Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPLAS PHARMACIE TOSTIVINT : revenue, balance sheet and financial ratios

SPFPLAS PHARMACIE TOSTIVINT is a French company founded 4 years ago, specialized in the sector Activités des sociétés holding. Based in SAINT-MICHEL-CHEF-CHEF (44730), this company of category PME shows in 2025 a net income positive of 131 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPLAS PHARMACIE TOSTIVINT (SIREN 912261336)
Indicator 2025 2023
Revenue N/C N/C
Net income 131 337 € -71 073 €
EBITDA N/C -71 021 €
Net margin N/C N/C

Revenue and income statement

In 2025, SPFPLAS PHARMACIE TOSTIVINT generates positive net income of 131 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

131 337 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 632%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 14%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

631.575%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

13.654%

Solvency indicators evolution
SPFPLAS PHARMACIE TOSTIVINT

Sector positioning

Debt ratio
631.58 2025
2023
2025
Q1: 0.04
Med: 8.09
Q3: 54.01
Average +50 pts over 2 years

In 2025, the debt ratio of SPFPLAS PHARMACIE TOSTIVINT (631.58) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
13.65% 2025
2023
2025
Q1: 21.27%
Med: 67.32%
Q3: 92.99%
Average

In 2025, the financial autonomy of SPFPLAS PHARMACIE TOSTIVINT (13.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
-22.59 years 2023
2023
Q1: 0.0 years
Med: 0.09 years
Q3: 3.23 years
Excellent

In 2023, the repayment capacity of SPFPLAS PHARMACIE TOSTIVINT (-22.59) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 5267.60. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

5267.603

Liquidity indicators evolution
SPFPLAS PHARMACIE TOSTIVINT

Sector positioning

Liquidity ratio
5267.6 2025
2023
2025
Q1: 161.8
Med: 834.57
Q3: 4761.54
Excellent +35 pts over 2 years

In 2025, the liquidity ratio of SPFPLAS PHARMACIE TOSTIVINT (5267.60) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
-8.05x 2023
2023
Q1: -65.31x
Med: 0.0x
Q3: 0.0x
Average

In 2023, the interest coverage of SPFPLAS PHARMACIE TOSTIVINT (-8.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SPFPLAS PHARMACIE TOSTIVINT

Positioning of SPFPLAS PHARMACIE TOSTIVINT in its sector

Comparison with sector Activités des sociétés holding

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (20 transactions). This range of 52 374€ to 1 614 035€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2025
Indicative
52k€ 269k€ 1614k€
269 743 € Range: 52 374€ - 1 614 035€
NAF 5 année 2025
How is this estimate calculated?

This estimate is based on the analysis of 20 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sociétés holding)

Compare SPFPLAS PHARMACIE TOSTIVINT with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sociétés holding

Frequently asked questions about SPFPLAS PHARMACIE TOSTIVINT

What is the revenue of SPFPLAS PHARMACIE TOSTIVINT ?

The revenue of SPFPLAS PHARMACIE TOSTIVINT is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPLAS PHARMACIE TOSTIVINT profitable?

Yes, SPFPLAS PHARMACIE TOSTIVINT generated a net profit of 131 k€ in 2025.

Where is the headquarters of SPFPLAS PHARMACIE TOSTIVINT ?

The headquarters of SPFPLAS PHARMACIE TOSTIVINT is located in SAINT-MICHEL-CHEF-CHEF (44730), in the department Loire-Atlantique.

Where to find the tax return of SPFPLAS PHARMACIE TOSTIVINT ?

The tax return of SPFPLAS PHARMACIE TOSTIVINT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPLAS PHARMACIE TOSTIVINT operate?

SPFPLAS PHARMACIE TOSTIVINT operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.